Hydroxycarbamide (HC)

[Edit]

Hydroxyurea; Droxia; Hydrea; Apo-Hydroxyurea

Hydroxycarbamide (HC)
Hydroxycarbamide is an antineoplastic drug, first synthesized in 1869, used in myeloproliferative disorders, specifically polycythemia vera and essential thrombocythemia. It is also used to reduce the rate of painful attacks in sickle-cell disease and has antiretroviral properties in diseases such as AIDS. Hydroxycarbamide decreases the production of deoxyribonucleotides via inhibition of the enzyme ribonucleotide reductase by scavenging tyrosyl free radicals as they are involved in the reduction NDPs.In the treatment of sickle-cell disease, hydroxycarbamide increases the concentration of fetal hemoglobin. The precise mechanism of action is not yet clear, but it appears that hydroxycarbamide increases nitric oxide levels, causing soluble guanylyl cyclase activation with a resultant rise in cyclic GMP, and the activation of gamma globin chain synthesis necessary for fetal hemoglobin production.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Hydroxycarbamide (HC) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Hydroxycarbamide (HC) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Hydroxycarbamide (HC) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Hydroxycarbamide (HC) CLIA Kit Customized Service Offer
n/a ELISA Kit for Hydroxycarbamide (HC) ELISA Kit Customized Service Offer